SIGN UP
LOG IN
Biodexa Pharma Advances Development eRapa, Oral Tablet Formulation Of Rapamycin, To Treat FAP Non-Surgically
Benzinga·07/28/2025 11:10:21
Listen to the news
Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company, reports making significant progress in developing eRapa, an oral tablet formulation of rapamycin, to treat FAP non-surgically. eRapa inhibits the mTOR (mammalian Target Of Rapamycin) protein. Too much mTOR has been linked to cancer and has been shown to be over-expressed in FAP polyps, thereby underscoring the rationale for using an mTOR inhibitor like eRapa to treat FAP.
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.